The goals of the Sample Procurement and Management Core (SPMC) are to optimize,promote and facilitate the research undertaken by the Center Investigators, as well as toenhance the interdisciplinary research capabilities between various Center laboratories and toexpedite human subjects research in a meaningful way. The SPMC will provide support toCenter Investigators and other users in terms of providing previously collected, de-identified,appropriately consented DMA and serum to projects, expanding DMA from existing resources orisolating additional DMA as needed from EBV-transformed cells lines, testing quality and quantityof outside and newly generated DMA and serum samples as needed, recruiting and enrollingfresh samples for project use, measuring autoantibodies in appropriate samples and managingsamples and data for the success of the Oklahoma Rheumatic Disease Research Cores Center(ORDRCC). As potential collaborators for all Core research projects, the SPMC will be anintegral part of the research team in the execution of research studies, as well as providingongoing sample and data management throughout the life of each individual project.The specific goals of the SPMC include:1. Facilitate access to human samples for research purposes. This goal includesserving as a central resource for Cores Center investigators to obtain appropriatelycollected DMA, serum, cells, clinical and de-identified clinical data.2. Facilitate human subject consent, recruitment and compliance. This goal includesconsenting, recruiting and obtaining samples from confirmation rheumatic diseasepatients for Core investigator projects, as well as assist with regulatory reporting.3. Facilitate the compilation and appropriate access to de-identified patientdemographic and clinical data from existing resources and management ofresearch data for Center Investigators. Consent, recruit and/or obtain samples fromconfirmatory lupus subsets or from patients with other systemic autoimmune rheumaticdiseases for feasibility and other projects for key Core investigators.4. Perform autoantibody testing for appropriate rheumatic disease patient sera.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053483-02
Application #
7673677
Study Section
Special Emphasis Panel (ZAR1)
Project Start
2008-09-01
Project End
2012-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
2
Fiscal Year
2008
Total Cost
$113,863
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Pelikan, Richard C; Kelly, Jennifer A; Fu, Yao et al. (2018) Enhancer histone-QTLs are enriched on autoimmune risk haplotypes and influence gene expression within chromatin networks. Nat Commun 9:2905
Patel, Zubin; Lu, Xiaoming; Miller, Daniel et al. (2018) A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet :
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247
Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531
Jog, Neelakshi R; Chakravarty, Eliza F; Guthridge, Joel M et al. (2018) Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Front Immunol 9:2198
Hanscombe, Ken B; Morris, David L; Noble, Janelle A et al. (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27:3813-3824
Bagavant, Harini; Dunkleberger, Micah L; Wolska, Nina et al. (2018) Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol :
Scofield, R Hal; Sharma, Rohan; Harris, Valerie M (2018) Reply. Arthritis Rheumatol 70:626-627
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2018) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:298-307
St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480

Showing the most recent 10 out of 284 publications